Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

20 July 2021
Pharma

Visiongain has published a new report entitled the Drug Delivery Technologies Market Report 2021-2031: Forecasts by Technology (Oral Drug Delivery Therapy, Injectable Drug Delivery, Topical Drug Delivery, Pulmonary Drug Delivery, Implantable Drug Delivery, Ocular Drug Delivery, Others), by Indication (Infectious Diseases, Cancer, Cardiovascular Diseases, Diabetes, Respiratory Diseases, Central Nervous System Disorders, Others), by Distribution Channel (Hospitals, Homecare Settings, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Drug Delivery Companies AND COVID-19 Recovery Scenarios.

The global drug delivery technologies market was valued at US$ US$xx bn in 2020 and is projected to grow at a CAGR of xx% during the forecast period 2021-2031. Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

How has COVID-19 had a significant negative impact on the Drug Delivery Technologies Market?
The COVID-19 pandemic has a significant negative impact on the Drug Delivery Technologies drug market globally. The COVID-19 outbreak in 2020 led to international border controls, country-wide lockdowns, pharmaceutical manufacturing restrictions & limitations. This pandemic has hampered the production and distribution of Drug Delivery Technologies.

COVID-19 would undoubtedly have an effect on chronic and infectious diseases patients and their care for the near future. Creating support networks for physicians and patients will help to break down walls and provide patients with appropriate access to potentially life-saving services. Companies are concerned about the COVID-19 epidemic's impact on supply and demand. All of these factors are having a negative impact on the drug delivery technologies sector, pushing the pharmaceutical industry and regulators to re-examine pharmaceutical supply chains.

How this Report Will Benefit you?
Visiongain’s 530+ page report provides 356 tables and 352 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the global drug delivery technologies market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for drug delivery technologies. Get the financial analysis of the overall market and different segments including therapy type, product & services, indication, and testing assay type and capture higher market share. We believe that high opportunity remains in this fast-growing drug delivery technologies market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report would help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.

What are the current market drivers?
Rise in consumption of drugs is expected to propel the demand for advanced drug delivery technology. According to the WHO, the prevalence of chronic illness cases is expected to increase by 57%, with higher illness cases in low- & middle-income nations. Additionally, the outbreak of pandemics in the current & past such as COVID19, SARS, Ebola, MERS, and H1N1 have added to the upsurge in drug consumption and vaccination.

Usage convenience and cost-effectiveness of drug delivery technology further driver the market adoption. Pharmaceutical companies like Pfizer, Roche, Novartis, GSK, and BDC are constantly investing in development of drug delivery systems to enhance the oral bioavailability of novel medicines using varied excipients. Also, the rising number of patients with chronic diseases along with growing healthcare awareness is projected to boost the demand for Drug Delivery Technologies.

Where are the market opportunities?
Rising adoption of self-administrative drug delivery methods is gaining popularity. Technological advantages are supporting the development of drug delivery methods that are easily understood and conveniently used by patients without constant supervision of medical practitioner. So, drug makers are drifting from conventional drug delivery techniques to the innovative and enhanced delivery techniques, thereby improving the drug solubility, dispersion, and targeting within the patient.

Escalating investments in drug development are creating opportunities for biopharmaceutical companies to innovate novel drug delivery techniques that offer higher solubility of drugs with self-administration. For increasing the efficacy of novel drugs, the companies develop the transportation system as well, which encourages the private and the public funding agencies to invest in research of drug delivery system. In 2020, Novus Therapeutics, entered into a second phase for clinical trial for its OP0201 product. The drug is developed is combination of surfactant molecule and nasal aerosol technique device.

Competitive Landscape
The major players operating in the drug delivery technologies market are Novartis AG, Gilead Sciences, Inc., GlaxoSmithKline, Pfizer Inc., F. Hoffmann-La Roche AG, Johnson & Johnson , Kindeva Drug Delivery, Eli Lilly and Company, AstraZeneca, Boehringer Ingelheim, Amgen Inc., Bristol Myers Squibb, Sanofi , Becton, Dickinson and Company (BD), Bayer AG.

Strategic collaboration, R&D investment, and geographic development are some of the primary strategies used by the market's leading companies to gain the largest revenue share. For instance, In May 2021, BD invested $200 mn to set up a drug delivery device plant in Zaragoza, Spain.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

Read

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

Read

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

Read

Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2021-2031

Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.

12 July 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever